Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Alpha-1 Antitrypsin Deficiency in COPD Patients: A Cross-Sectional Study.

Sorroche PB, Fernández Acquier M, López Jove O, Giugno E, Pace S, Livellara B, Legal S, Oyhamburu J, Saez MS.

Arch Bronconeumol. 2015 Nov;51(11):539-43. doi: 10.1016/j.arbres.2015.01.008. Epub 2015 Mar 21. English, Spanish.

2.

Tiotropium Respimat inhaler and the risk of death in COPD.

Wise RA, Anzueto A, Cotton D, Dahl R, Devins T, Disse B, Dusser D, Joseph E, Kattenbeck S, Koenen-Bergmann M, Pledger G, Calverley P; TIOSPIR Investigators..

N Engl J Med. 2013 Oct 17;369(16):1491-501. doi: 10.1056/NEJMoa1303342. Epub 2013 Aug 30.

3.

[Guidelines for COPD prevention, diagnosis and treatment in Argentina].

Figueroa Casas JC, Schiavi E, Mazzei JA, López AM, Rhodius E, Ciruzzi J, Sívori M; Grupo Recomendaciones De EPOC.; Asociacion Argentina De Medicina Respiratoria..

Medicina (B Aires). 2012;72 Suppl 1:1-33. Spanish.

4.

FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.

Low DE, File TM Jr, Eckburg PB, Talbot GH, David Friedland H, Lee J, Llorens L, Critchley IA, Thye DA; FOCUS 2 investigators..

J Antimicrob Chemother. 2011 Apr;66 Suppl 3:iii33-44. doi: 10.1093/jac/dkr097.

PMID:
21482568
5.

Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial.

Troosters T, Celli B, Lystig T, Kesten S, Mehra S, Tashkin DP, Decramer M; Uplift Investigators..

Eur Respir J. 2010 Jul;36(1):65-73. doi: 10.1183/09031936.00127809. Epub 2010 Feb 25.

6.

Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial.

Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP; UPLIFT investigators..

Lancet. 2009 Oct 3;374(9696):1171-8. doi: 10.1016/S0140-6736(09)61298-8. Epub 2009 Aug 27.

PMID:
19716598
7.

A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD.

Vestbo J, Tan L, Atkinson G, Ward J; UK-500,001 Global Study Team..

Eur Respir J. 2009 May;33(5):1039-44. doi: 10.1183/09031936.00068908. Epub 2009 Feb 12.

8.

A 4-year trial of tiotropium in chronic obstructive pulmonary disease.

Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M; UPLIFT Study Investigators..

N Engl J Med. 2008 Oct 9;359(15):1543-54. doi: 10.1056/NEJMoa0805800. Epub 2008 Oct 5.

9.

Geographic differences in clinical characteristics and management of COPD: the EPOCA study.

Miravitlles M, Murio C, Tirado-Conde G, Levy G, Muellerova H, Soriano JB, Ramirez-Venegas A, Ko FW, Canelos-Estrella B, Giugno E, Bergna M, Chérrez I, Anzueto A.

Int J Chron Obstruct Pulmon Dis. 2008;3(4):803-14.

10.

[Non invasive positive pressure ventilation in patients with COPD exacerbation].

Caberlotto OJ, Acquier MF, Grodnisky L, Malamud P, Gramblika G, Giugno E.

Medicina (B Aires). 2007;67(2):120-4. Spanish.

PMID:
17593594
11.

[Updated Argentine consensus on chronic obstructive pulmonary disease].

Gené RJ, Giugno ER, Abbate EH, Figueroa-Casas JC, Mazzei JA, Schiavi EA.

Medicina (B Aires). 2003;63(5):419-46. Review. Spanish.

PMID:
14628655

Supplemental Content

Loading ...
Support Center